MBX Biosciences, Inc. Common Stock - Asset Resilience Ratio
MBX Biosciences, Inc. Common Stock (MBX) has an Asset Resilience Ratio of 87.20% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See MBX financial flexibility score to measure the company's free cash flow as a share of total liabilities.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how MBX Biosciences, Inc. Common Stock's Asset Resilience Ratio has changed over time. See MBX equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down MBX Biosciences, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MBX Biosciences, Inc. Common Stock (MBX) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $394.76 Million | 87.2% |
| Total Liquid Assets | $394.76 Million | 87.20% |
Asset Resilience Insights
- Very High Liquidity: MBX Biosciences, Inc. Common Stock maintains exceptional liquid asset reserves at 87.20% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
MBX Biosciences, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare MBX Biosciences, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for MBX Biosciences, Inc. Common Stock (2022–2025)
The table below shows the annual Asset Resilience Ratio data for MBX Biosciences, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 77.48% | $298.42 Million | $385.14 Million | -1.76pp |
| 2024-12-31 | 79.24% | $212.80 Million | $268.54 Million | +19.67pp |
| 2023-12-31 | 59.58% | $50.15 Million | $84.18 Million | +19.11pp |
| 2022-12-31 | 40.47% | $18.25 Million | $45.09 Million | -- |
About MBX Biosciences, Inc. Common Stock
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also devel… Read more